-
2 Takes On SmileDirectClub's First Quarterly Print As Public Company
Wednesday, November 13, 2019 - 3:55pm | 471Read More...SmileDirectClub Inc (NASDAQ: SDC) reported third-quarter results Tuesday that were "good enough" in one Street analyst's view, while another found fault in management's fourth-quarter outlook. The Analysts Bank of America Merrill Lynch analyst Michael Ryskin maintained a Buy...
-
Fulgent Is 'Making A Splash' In The Genetics Pool
Monday, October 24, 2016 - 9:29am | 389Read More...Credit Suisse has started coverage of Fulgent Genetics Inc (NASDAQ: FLGT) with an Outperform rating and price target of $13, saying proprietary technology and cost advantages should double the company’s test volume in 2016 and 2017, triggering revenue growth of 90 percent and 98 percent,...
-
Credit Suisse Impressed By Lantheus Holdings' Market Leadership, But Wary Of Increasing Competition
Friday, September 23, 2016 - 10:53am | 388Read More...Credit Suisse assumed coverage of Lantheus Holdings Inc (NASDAQ: LNTH) with a Neutral rating and $8 price target, as it is wary of heightened competition despite acknowledging the company's market leadership in DEFINITY/Xenon franchises, strong industry fundamentals and pipeline opportunities....
-
Credit Suisse Initiates Medpace At Outperform, Says Co. Should Outgrow Industry
Tuesday, September 6, 2016 - 11:51am | 344Read More...Credit Suisse has started coverage of Medpace Holdings Inc (NASDAQ: MEDP) with an Outperform rating, saying the contract research organization should benefit from a strong fundamental backdrop while having a competitive advantage due to its scientifically-driven full-service approach. The brokerage...
-
Credit Suisse Starts Patheon At Neutral Following Nearly 30% Rally
Tuesday, August 16, 2016 - 10:15am | 353Read More...Patheon NV (NYSE: PTHN) shares have appreciated 29 percent since the IPO on July 21, and the stock is currently trading at a 10 percent premium to the relevant pharmaceutical outsourcing companies. Credit Suisse’s Erin Wilson initiated coverage of the company with a Neutral rating and price...
-
Credit Suisse Sets New Outperform Rating, $75 Target On PAREXEL
Tuesday, June 21, 2016 - 9:03am | 260Read More...With PAREXEL International Corporation’s (NASDAQ: PRXL) shares down 16 percent year-to-date, Credit Suisse’s Erin Wilson views the stock valuation as attractive. Wilson initiated coverage of the company with an Outperform rating and price target of $75. Industry Leading Growth The...
-
PRA Health Shares Initiated Neutral By Credit Suisse
Tuesday, June 21, 2016 - 8:52am | 275Read More...PRA Health Sciences Inc (NASDAQ: PRAH) shares have declined 6 percent since the secondary offering in May. Credit Suisse’s Erin Wilson initiated coverage of the company with a Neutral rating and price target of $43. Competitive Advantage “As the fifth largest contract research...
-
Credit Suisse Says Premium Valuation In INC Research Is 'Warranted'
Tuesday, June 21, 2016 - 8:41am | 261Read More...INC Research Holdings Inc (NASDAQ: INCR) shares have lost 14 percent since May 23. Credit Suisse’s Erin Wilson initiated coverage of the company with an Outperform rating and a price target of $51. The analyst believes the company is poised for industry-leading double-digit revenue and EPS...
-
Positives In Charles River Labs 'Largely Reflected In Industry-High Valuation'
Tuesday, June 21, 2016 - 8:03am | 325Read More...Shares of Charles River Laboratories Intl. Inc (NYSE: CRL) have gained 12 percent since March 21. Credit Suisse’s Erin Wilson initiated coverage of the company with a Neutral rating and a price target of $84. While Charles River Labs has exhibited solid execution against a strong...
-
UPDATE: Bank Of America Upgrades Abaxis
Monday, July 28, 2014 - 9:30am | 132Read More...In a report released Monday, Bank of America analyst Erin Wilson upgraded Abaxis (NASDAQ: ABAX) from Underperform to Neutral, while increasing its price objective from $36 to $48. Analysts at Bank of America see market share expansion with IDEXX Laboratories (NASDAQ: IDXX) limit the selling of...
